<DOC>
	<DOCNO>NCT01272102</DOCNO>
	<brief_summary>To determine area Receiver Operator Characteristic Curve ( AUC ) Ganglion Cell Analysis ( GCA ) average thickness .</brief_summary>
	<brief_title>Macular Ganglion Cell Analysis ( GCA ) Cirrus HD-OCT Glaucoma</brief_title>
	<detailed_description>To determine area Receiver Operator Characteristic Curve ( AUC ) follow GCA parameter : 1 . Minimum thickness 2 . Supero-temporal thickness 3 . Superior thickness 4 . Supero-nasal thickness 5 . Infero-temporal thickness 6 . Inferior thickness 7 . Infero-nasal thickness</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<criteria>Age 40 year old Diagnosed glaucoma Principal Investigator coinvestigator Able willing make require study visit Able willing give consent follow study instruction Ophthalmic : Best correct visual acuity either eye bad 20/40 Snellen chart Snellen equivalent acuity chart . Refractive error outside 12.00D +8.00D spherical range &gt; 3.00D cylinder . Previous vitreoretinal surgery study eye . Vitreoretinal traction epiretinal membrane study eye . Any active infection anterior posterior segment . Evidence diabetic retinopathy , diabetic macular edema , vitreoretinal disease study eye upon dilated examination , upon evaluation retinal photo . Systemic : History diabetes , leukemia , AIDS , uncontrolled systemic hypertension , dementia multiple sclerosis . A life threaten debilitate disease . Participation study involve nonFDA approve investigational drug ( IND ) within past month , ongoing participation study nonFDA approve cleared investigational device ( IDE ) . Current recent ( within past 14 day ) use agent photosensitizing property route ( e.g. , Visudyne® , ciprofloxacin , Bactrim® , doxycycline , etc. ) . Concomitant use hydrochloroquine and/or chloroquine .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>